Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

215 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
One versus two high-dose cytarabine-based consolidation before autologous stem cell transplantation for young acute myeloblastic leukaemia patients in first complete remission.
Jourdan E, Rigal-Huguet F, Marit G, Vey N, Dastugue N, Fegueux N, Molina L, Gastaut JA, Legros L, Zerazhi H, Cailleres S, Bauduer F, Bordessoule D, Attal M, Blaise D, Pigneux A; BGMT Study Group. Jourdan E, et al. Among authors: bordessoule d. Br J Haematol. 2005 May;129(3):403-10. doi: 10.1111/j.1365-2141.2005.05470.x. Br J Haematol. 2005. PMID: 15842665 Free article. Clinical Trial.
Bortezomib combined with low-dose cytarabine in Intermediate-2 and high risk myelodysplastic syndromes. A phase I/II Study by the GFM.
Natarajan-Amé S, Park S, Ades L, Vey N, Guerci-Bresler A, Cahn JY, Etienne G, Bordessoule D, Ravoet C, Legros L, Cheze S, Stamatoullas A, Berger E, Schmidt A, Charbonnier A, Chaury MP, Braun T, Fenaux P, Dreyfus F; Groupe Francophone des Myélodysplasies (GFM). Natarajan-Amé S, et al. Among authors: bordessoule d. Br J Haematol. 2012 Jul;158(2):232-237. doi: 10.1111/j.1365-2141.2012.09153.x. Epub 2012 May 10. Br J Haematol. 2012. PMID: 22571447 Free article. Clinical Trial.
A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher-Risk MDS or low blast AML: GFM's "pick a winner" trial, with the impact of somatic mutations.
Adès L, Duployez N, Guerci-Bresler A, Laribi K, Peterlin P, Vey N, Thepot S, Wickenhauser S, Zerazhi H, Stamatoullas A, Wattel E, Recher C, Toma A, Dimicoli-Salazar S, Braun T, Beyne-Rauzy O, Marolleau JP, Cheze S, Park S, Cluzeau T, Nimubona S, Bordessoule D, Benramdane R, Quesnel B, Amé S, de Botton S, Chermat F, Preudhomme C, Chevret S, Fenaux P. Adès L, et al. Among authors: bordessoule d. Br J Haematol. 2022 Aug;198(3):535-544. doi: 10.1111/bjh.18193. Epub 2022 Apr 19. Br J Haematol. 2022. PMID: 35438802 Clinical Trial.
High CD3+ and CD34+ peripheral blood stem cell grafts content is associated with increased risk of graft-versus-host disease without beneficial effect on disease control after reduced-intensity conditioning allogeneic transplantation from matched unrelated donors for acute myeloid leukemia - an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Czerw T, Labopin M, Schmid C, Cornelissen JJ, Chevallier P, Blaise D, Kuball J, Vigouroux S, Garban F, Lioure B, Fegueux N, Clement L, Sandstedt A, Maertens J, Guillerm G, Bordessoule D, Mohty M, Nagler A. Czerw T, et al. Among authors: bordessoule d. Oncotarget. 2016 May 10;7(19):27255-66. doi: 10.18632/oncotarget.8463. Oncotarget. 2016. PMID: 27036034 Free PMC article.
Myelodysplastic syndromes with single neutropenia or thrombocytopenia are rarely refractory cytopenias with unilineage dysplasia by World Health Organization 2008 criteria and have favourable prognosis.
Gyan E, Andrieu V, Sanna A, Caille A, Schemenau J, Sudaka I, Siguret V, Malet M, Park S, Bordessoule D, Mairesse J, Gelsi-Boyer V, Cheze S, Beyne-Rauzy O, Sébert M, Sapena R, Zerazhi H, Legros L, Guerci-Bresler A, Amé SN, Germing U, Santini V, Salvi F, Gioia D, Lunghi M, Dreyfus F, Fenaux P; Groupe Francophone des Myélodysplasies, Fondazione Italiana per le Sindromi Mielodisplastiche (FISMonlus), and Düsseldorf MDS Registry. Gyan E, et al. Among authors: bordessoule d. Br J Haematol. 2016 Dec;175(5):975-979. doi: 10.1111/bjh.13902. Epub 2016 Jan 15. Br J Haematol. 2016. PMID: 26773632 Free article. No abstract available.
Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia.
Malfuson JV, Etienne A, Turlure P, de Revel T, Thomas X, Contentin N, Terré C, Rigaudeau S, Bordessoule D, Vey N, Gardin C, Dombret H; Acute Leukemia French Association (ALFA). Malfuson JV, et al. Among authors: bordessoule d. Haematologica. 2008 Dec;93(12):1806-13. doi: 10.3324/haematol.13309. Epub 2008 Oct 6. Haematologica. 2008. PMID: 18838471 Free article.
Azacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries.
Díez-Campelo M, Lorenzo JI, Itzykson R, Rojas SM, Berthon C, Luño E, Beyne-Rauzy O, Perez-Oteyza J, Vey N, Bargay J, Park S, Cedena T, Bordessoule D, Muñoz JA, Gyan E, Such E, Visanica S, López-Cadenas F, de Botton S, Hernández-Rivas JM, Ame S, Stamatoullas A, Delaunay J, Salanoubat C, Isnard F, Guieze R, Pérez Guallar J, Badiella L, Sanz G, Cañizo C, Fenaux P. Díez-Campelo M, et al. Among authors: bordessoule d. Br J Haematol. 2018 May;181(3):350-359. doi: 10.1111/bjh.15190. Epub 2018 Apr 2. Br J Haematol. 2018. PMID: 29611196 Free article. Clinical Trial.
A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission.
Vey N, Bourhis JH, Boissel N, Bordessoule D, Prebet T, Charbonnier A, Etienne A, Andre P, Romagne F, Benson D, Dombret H, Olive D. Vey N, et al. Among authors: bordessoule d. Blood. 2012 Nov 22;120(22):4317-23. doi: 10.1182/blood-2012-06-437558. Epub 2012 Sep 21. Blood. 2012. PMID: 23002117 Free article. Clinical Trial.
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.
Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, Lefort S, Marit G, Macro M, Sebban C, Belhadj K, Bordessoule D, Fermé C, Tilly H. Coiffier B, et al. Among authors: bordessoule d. Blood. 2010 Sep 23;116(12):2040-5. doi: 10.1182/blood-2010-03-276246. Epub 2010 Jun 14. Blood. 2010. PMID: 20548096 Free PMC article. Clinical Trial.
Reducing mortality in newly diagnosed standard-risk acute promyelocytic leukemia in elderly patients treated with arsenic trioxide requires major reduction of chemotherapy: a report by the French Belgian Swiss APL group (APL 2006 trial).
Rahmé R, Ades L, Thomas X, Guerci-Bresler A, Pigneux A, Vey N, Raffoux E, Castaigne S, Spertini O, Wittnebel S, Marolleau JP, Damaj G, Bordessoule D, Lejeune J, Chevret S, Fenaux P. Rahmé R, et al. Among authors: bordessoule d. Haematologica. 2018 Nov;103(11):e519-e521. doi: 10.3324/haematol.2018.193151. Epub 2018 May 24. Haematologica. 2018. PMID: 29794147 Free PMC article. Clinical Trial. No abstract available.
215 results